PARP inhibitors

Xem 1-6 trên 6 kết quả PARP inhibitors

Landscape of homologous recombination deficiencies in solid tumours: Analyses of two independent genomic datasets

DNA repair deficiencies are characteristic of cancer and homologous recombination deficiency (HRD) is the most common. HRD sensitizes tumour cells to PARP inhibitors so it is important to understand the landscape of HRD across diferent solid tumour types. Methods: Germline and somatic BRCA mu

13p vielonmusk 21-01-2022 17 2 Download

A phase IA dose-escalation study of PHI101, a new checkpoint kinase 2 inhibitor, for platinum-resistant recurrent ovarian cancer

PHI-101 is an orally available, selective checkpoint kinase 2 (Chk2) inhibitor. PHI-101 has shown antitumour activity in ovarian cancer cell lines and impaired DNA repair pathways in preclinical experiments. Furthermore, the in vivo study suggests the synergistic effect of PHI-101 through combination with PARP inhibitors for ovarian cancer treatment.

7p vielonmusk 21-01-2022 20 2 Download

Clinical significance of metabolism-related genes and FAK activity in ovarian high-grade serous carcinoma

Administration of poly (ADP-ribose) polymerase (PARP) inhibitors after achieving a response to platinum-containing drugs significantly prolonged relapse-free survival compared to placebo administration. PARP inhibitors have been used in clinical practice. However, patients with platinum-resistant relapsed ovarian cancer still have a poor prognosis and there is an unmet need.

11p vielonmusk 21-01-2022 11 2 Download
Báo cáo khoa học: Benzamide and 4-amino 1,8 naphthalimide treatment inhibit telomerase activity by down-regulating the expression of telomerase associated protein and inhibiting the poly(ADP-ribosyl)ation of telomerase reverse transcriptase in cultured cells

To test the role of poly(ADP-ribose) polymerase on the telomerase activity, we determined the telomerase activity in leukemic cells K562 treated with benzamide and 4-amino 1,8 naphthalimide (NAP), the inhibitors of PARP. We observed that both the agents inhibited telomerase activity in a dose-dependent manner. The doses of benzamide and NAP that inhibited telo-merase activity to 50% of untreated control cells were 10.7 ± 0.6 mmand 200 ± 7lm, respectively.

12p fptmusic 11-04-2013 47 2 Download
Báo cáo y học: " Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP"

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Novel targeted therapeutics: inhibitors of MDM2, ALK and PARP...

14p thulanh25 06-12-2011 42 5 Download
Báo cáo y học: "PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers"

Tuyển tập các báo cáo nghiên cứu khoa học ngành y học tạp chí Medical Sciences dành cho các bạn sinh viên ngành y tham khảo đề tài: PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers?

7p thulanh9 07-10-2011 45 3 Download